These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25381972)

  • 1. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?
    Conti A; Esposito I; Lasagni C; Miglietta R; Padalino C; Fabiano A; Pellacani G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S35-7. PubMed ID: 25381972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.
    Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1444-8. PubMed ID: 21834947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with psoriasis treated with biological drugs needing a surgical treatment.
    Fabiano A; De Simone C; Gisondi P; Piaserico S; Lasagni C; Pellacani G; Conti A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S24-6. PubMed ID: 25381969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viewpoint on handling anti-TNF failure in psoriasis.
    Bracke S; Lambert J
    Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
    Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
    Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.